Skip to content

Alkermes ALKS Quick ratio

Quick ratio at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
1.3×+0.1×
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
1.8×-1.1×
AbbVie logo
AbbVieABBV
0.7×0.0×
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
1.3×-0.6×
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
4.1×-5.5×
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
2.9×-0.2×

Other financials

Income statement

See full
Revenue$392.9M+28.2%
Gross profit$331.3M+28.8%
Operating income-$48.3M-450%
Net income-$66.5M-396%
EPS (diluted)-$0.40-408%

Balance sheet

See full
Cash & equivalents$351.6M-12.1%
Total debt$1.6B+2,034%
Total equity$1.8B+15.9%
Total assets$4.3B+105%

Cash flow

See full
Operating cash flow-$165.7M-268%
CapEx$4.1M-59.5%
Free cash flow-$169.8M-291%

Valuation

See full
Market cap$7.5B+9.7%
Enterprise value$8.73B+41.2%
P/E49.1×+29.7×
P/S4.8×+0.3×

Profitability

See full
Gross margin86.6%+2.2pp
Operating margin12.3%-13.6pp
Net margin9.8%-13.5pp
FCF margin14.2%-17.6pp

Returns & leverage

See full
Return on equity9.4%-16.1pp
Debt / equity0.9×+0.9×
Current ratio2.3×-1.1×

Where this comes from

Calculated from Alkermes’s reported figures.

Based on the most recent quarter.

The official record: Alkermes’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alkermes's quick ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alkermes's quick ratio?
Alkermes (ALKS) reported quick ratio of 1.7× in Q1 2026.
How has Alkermes's quick ratio changed year-over-year?
Alkermes's quick ratio decreased by 41.6% year-over-year, from 2.9× to 1.7×.
What is the long-term trend for Alkermes's quick ratio?
Over 5 years (2020 to 2025), Alkermes's quick ratio has grown at a 7.2% compound annual growth rate (CAGR), from 2.2× to 3.2×.
What does quick ratio mean?
Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.